Tafenoquine: a toxicity overview
Introduction: A century-long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted in the approval of tafenoquine by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) and to date registration in Bra...
Saved in:
Main Authors: | Cindy S. Chu, Jimee Hwang |
---|---|
Other Authors: | Faculty of Tropical Medicine, Mahidol University |
Format: | Review |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/78866 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Tafenoquine - A radical improvement?
by: Nicholas J. White
Published: (2020) -
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
by: James Watson, et al.
Published: (2019) -
The Antimalarial Activity of Tafenoquine in Falciparum Malaria
by: White N.J.
Published: (2023) -
Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
by: Alejandro Llanos-Cuentas, et al.
Published: (2020) -
Tafenoquine for the prevention of Plasmodium vivax malaria relapse
by: James A. Watson, et al.
Published: (2022)